Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine

Headache

Volumn 48, Issue 2, 2008, Pages 236-247

  Chen, Li Chia ^a   Ashcroft, Darren M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Meta analysis; Migraine; Systematic review; Zolmitriptan

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ELETRIPTAN; METOCLOPRAMIDE; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ARTICLE; ASTHENIA; CHEST RELATED SYNDROME; CLINICAL TRIAL; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; MIGRAINE; PRIORITY JOURNAL; RISK; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYSTEMATIC REVIEW; TABLET; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 38749140626     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.01007.x     Document Type: Article

References (45)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004 24 Suppl. 1) 9 160.
2. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache. 1994 34 : 319 328.
3. Lipton RB, Stewart WF, Von KM. The burden of migraine. A review of cost to society. Pharmacoeconomics. 1994 6 : 215 221.
4. 1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002 22 : 633 658.
5. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 55 : 754 762.
6. Spencer CM, Gunasekara NS, Hills C. Zolmitriptan. A review of its use in migraine. Drugs. 1999 58 : 347 374.
7. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations: How to match patients and products. CNS Drugs. 2003 17 : 431 447.
8. Pharmaceutical Research and Manufacturers of America. Clinical study results database. Available at: http://www.clinicalstudyresults.org. Accessed 15 December, 2006.
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996 17 : 1 12.
10. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol. 1991 31 : 295 299.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 7 : 177 188.
12. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004 23 : 1351 1375.
13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 21 : 1539 1558.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 327 : 557 560.
15. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: A multicenter, double-blind, placebo-controlled dose range-findings study. Neurology. 1997 49 : 1210 1218.
16. Solomon GD, Cady RK, Klapper JA, Earl NL, Super JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology. 1997 49 : 1219 1225.
17. Tepper SJ, Donnan GA, Dowson AJ, et al. A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin. 1999 15 : 254 271.
18. Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: High placebo responses in adolescents. Headache. 2006 46 : 101 109.
19. Gallagher RM, Dennish G, Spierings ELH, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache. 2000 40 : 119 128.
20. Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: A double-blind, randomised, three-attack study. Eur Neurol. 2002 47 : 88 98.
21. Gruffyd-Jones K, Kies B, Middleton A, Mulder LJMM, Rosjo O, Millson DS. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: A randomized, double-blind, international study. Eur J Neurol. 2001 8 : 237 245.
22. Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand. 2007 115 : 34 40.
23. Geraud G, Olesen J, Pfaffenrath V, et al. Comparison of the efficacy of zolmitriptan and sumatriptan: Issues in migraine trial design. Cephalalgia. 2000 20 : 30 38.
24. Pascual J, Vega P, Diener H-C, et al. Comparison of rizatriptan 10 mg vs zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia. 2000 20 : 455 461.
25. Schoenen J, Jones M, Kane K, van Assche P, Saiers J. Naratriptan 2.5 mg tablets have a similar efficacy in the acute treatment of migraine as zolmitriptan 2.5 mg tablets, but exhibit a longer duration of action and are better tolerated: Results of a comparator study. The 51th Annual Meeting of American Academy of Neurology, Toronto. 1999.
26. Steiner TJ, Diener H-C, MacGregor EA, Schoenen J, Muirhead N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia. 2003 23 : 942 952.
27. AstraZeneca. A multi-centre, randomised, double-blind trial to compare the efficacy and safety of Zomig 2.5 mg, Naramig 2.5 mg and placebo in the acute tratment of adult patients with migraine. Protocol 311CIL/0099. Available at: http://www.astrazenecaclinicaltrials.com/Article/515074.aspx. Accessed 13 February, 2006. 2005.
28. Gawel M, Aschoff J, May A, Charlesworth BR. Zolmitriptan 5 mg nasal spray: Efficacy and onset of action in the acute treatment of migraine - Results from phase 1 of the REALIZE study. Headache. 2005 45 : 7 16.
29. Loder E, Freitag FG, Adelman J, Pearlman S, bu-Shakra S. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: Results of a large double-blind placebo-controlled trial. Curr Med Res Opin. 2005 21 : 381 389.
30. Klapper J, Lucas C, Rosjo O, Charlesworth B. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004 24 : 918 924.
31. Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003 17 : 653 667.
32. Ioannidis JP, Contopoulos-Ioannidis DG. Reporting of safety data from randomised trials. Lancet. 1998 352 : 1752 1753.
33. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: Quantitative systematic review. Pain. 2002 97 : 247 257.
34. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs. 2001 10 : 1831 1845.
35. Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O'Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000 40 : 513 520.
36. Mathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: A comparative open trial. Headache. 2000 40 : 464 465.
37. Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Headache. 2005 45 : 874 882.
38. Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003 23 : 463 471.
39. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5-HT(1D) receptor agonist in the acute oral treatment of migraine: A double-blind, placebo-controlled, dose-range finding study. Neurology. 1996 46 : 522 526.
40. Dahlof C, Diener H-C, Goadsby PJ, et al. Zolmitriptan, a 5-HT(1B/1D) receptor agonist for the acute oral treatment of migraine: A multicentre, dose-range finding study. Eur J Neurol. 1998 5 : 535 543.
41. Ryan RE Jr., Diamond S, Giammarco RAM, Aurora SK, Reed RC, Fletcher PE. Efficacy of zolmitriptan at early time-points for the acute treatment of migraine and treatment of recurrence: A randomised, placebo-controlled trial. CNS Drugs. 2000 13 : 215 226.
42. Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia. 2002 22 : 101 106.
43. Sakai F, Iwata M, Tashiro K, et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: A dose-response study. Cephalalgia. 2002 22 : 376 383.
44. Spierings ELH, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs. 2004 18 : 1133 1141.
45. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double-blind, placebo-controlled study. CNS Drugs. 2005 19 : 125 136.